FDAnews Drug Daily Bulletin

Barr Laboratories and Duramed Pharmaceuticals, both subsidiaries of Barr Pharmaceuticals, have entered into a $2 million settlement agreement with the Massachusetts attorney general to resolve Medicaid price reporting litigation, Attorney General Martha Coakley’s office announced.

The commonwealth had sued 13 generic drugmakers in the U.S District Court for the District of Massachusetts in 2003 for allegedly inflating the prices they reported to national price reporting services.

The other companies involved with the suit are Mylan, Ivax, Warrick Pharmaceuticals, Watson Pharmaceuticals, Schein Pharmaceutical, Teva Pharmaceuticals, Par Pharmaceutical, Purepac Pharmaceutical and Roxane Laboratories, according to court records. The commonwealth already has settled with Ethex and Dey.

The claims against Barr and Duramed were related to methotrexate, naltrexone HCl, warfarin sodium, Apri (desogestrel/ethinyl estradiol) and digoxin, the attorney general said.